RBIO 101
Alternative Names: AAV.CYP4V2 - Reflection Biotechnologies; RBIO-101Latest Information Update: 28 Sep 2022
At a glance
- Originator Reflection Biotechnologies
- Developer Columbia University; Reflection Biotechnologies
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bietti crystalline dystrophy
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Retinal dystrophies in USA
- 28 Aug 2018 Preclinical trials in Bietti crystalline dystrophy in USA (unspecified route) prior to August 2018
- 28 Aug 2018 RBIO 101 receives Orphan Drug status for Bietti crystalline dystrophy in USA